CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to NVO

Ziltivekimab

Phase 3
Novo Nordisk A/S (NVO)

Phase 3

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History
Sep '26
NVOPhase 3
✓Completed

Ziltivekimab Phase 3 Est. Readout

Ziltivekimab
Sep 2026~
CT.gov
Drug Information

Target Indication

Heart Failure

Clinical Trial

NCT05636176

Last updated: 12/10/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.